ArticleAmerican journal of translational research2026
Elevated P-RBC complexes are associated with thrombotic risk and diagnostic potential in myeloproliferative neoplasms: a retrospective cohort study.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by excessive myeloid proliferation. The impaired clearance of senescent erythrocytes is a key pathological feature, yet its mechanisms remain unclear. Pro-phagocytic platelet-erythrocyte (P-RBC) complexes may represent a novel intercellular interaction involved in this process.
objectiveTo investigate the levels of P-RBC complexes in MPN patients, their association with clinical characteristics and thrombotic risk, and their potential diagnostic value.
methodsIn this retrospective cohort study, 152 MPN patients (including polycythemia vera [PV], essential thrombocythemia [ET], and primary myelofibrosis [PMF]) and 152 healthy controls were enrolled. P-RBC complex levels in peripheral blood were measured using flow cytometry. Correlations with laboratory parameters, thrombotic events, and survival were analyzed.
resultsP-RBC complex levels were significantly higher in MPN patients than in controls (2.76 ± 0.53% vs. 1.28 ± 0.37%, P < 0.001). Levels varied by subtype, with PMF patients showing the highest levels (3.28 ± 0.52%), followed by PV (2.76 ± 0.44%) and ET (2.49 ± 0.39%) (P < 0.001). P-RBC levels positively correlated with hemoglobin (r = 0.456), C-reactive protein (r = 0.291), and lactate dehydrogenase (r = 0.736) (all P < 0.001). Patients with thrombotic events had higher P-RBC levels than those without (3.04 ± 0.70% vs. 2.72 ± 0.48%, P = 0.009). Multivariate analysis identified P-RBC level as an independent risk factor for thrombosis (OR = 3.07, P = 0.012). Although survival was worse in the high-P-RBC group, the difference was not statistically significant (P = 0.194). ROC analysis showed excellent diagnostic performance for MPNs (AUC = 0.990), with 100.0% sensitivity and 91.4% specificity at a 1.80% cutoff.
conclusionP-RBC complexes are significantly elevated in MPN patients and correlate with disease subtype, inflammation, and thrombotic risk. They represent a promising novel biomarker for MPN diagnosis and risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.